The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial
Open accessAbstract
Importance: Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF. Objective: To assess the effect of high-dose spironolactone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with usual care alone. Design, Setting, and Participants: This double-blind and placebo (or low-dose)-controlled randomized clinical trial was conducted in 22 US acute care hospitals among patients with AHF who were previously receiving no or low-dose (12.5 mg or 25 mg daily) spironolactone and had NT-proBNP levels of 1000 pg/mL or more or B-type natriuretic peptide levels of 250 pg/mL or more, regardless of ejection fraction. Interventions: High-dose spironolactone (100 mg) vs placebo or 25 mg spironolactone (usual care) daily for 96 hours. Main Outcomes and Measures: The primary end point was the change in NT-proBNP levels from baseline to 96 hours. Secondary end points included the clinical congestion score, dyspnea assessment, net urine output, and net weight change. Safety end points included hyperkalemia and changes in renal function. Results: A total of 360 patients were randomized, of whom the median age was 65 years, 129 (36%) were women, 200 (55.5%) were white, 151 (42%) were black, 8 (2%) were Hispanic or Latino, 9 (2.5%) were of other race/ethnicity, and the median left ventricular ejection fraction was 34%. Baseline median (interquartile range) NT-proBNP levels were 4601 (2697-9596) pg/mL among the group treated with high-dose spironolactone and 3753 (1968-7633) pg/mL among the group who received usual care. There was no significant difference in the log NT-proBNP reduction between the 2 groups (-0.55 [95% CI, -0.92 to -0.18] with high-dose spironolactone and -0.49 [95% CI, -0.98 to -0.14] with usual care, P = .57). None of the secondary end point or day-30 all-cause mortality or heart failure hospitalization rate differed between the 2 groups. The changes in serum potassium and estimated glomerular filtration rate at 24, 48, 72, and 96 hours. were similar between the 2 groups. Conclusions and Relevance: Adding treatment with high-dose spironolactone to usual care for patients with AHF for 96 hours was well tolerated but did not improve the primary or secondary efficacy end points. Trial Registration: clinicaltrials.gov Identifier: NCT02235077.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000366 · Cited by 2,466
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationChen, J., Normand, S.-L. T., Wang, Y., & Krumholz, H. M. (2011) · JAMA · doi:10.1001/jama.2011.1474 · Cited by 742
Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome
Obi, Y., Kim, T., Kovesdy, C. P., Amin, A. N., & Kalantar-Zadeh, K. (2016) · Cardiorenal Medicine · doi:10.1159/000441283 · Cited by 614
Ambrosy, A. P., Pang, P. S., Khan, S., Konstam, M. A., Fonarow, G. C., Traver, B., Maggioni, A. P., Cook, T., Swedberg, K., Burnett, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs444 · Cited by 583
Self-citationChen, H. H., Anstrom, K. J., Givertz, M. M., Stevenson, L. W., Semigran, M. J., Goldsmith, S. R., Bart, B. A., Bull, D. A., Stehlik, J., LeWinter, M. M., et al. (2013) · JAMA · doi:10.1001/jama.2013.282190 · Cited by 458
Self-citationvan Vliet, A., Donker, A. J. M., Nauta, J. J. P., & Verheugt, F. W. A. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90241-4 · Cited by 173
Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials
Lachin, J. M. (1999) · Controlled Clinical Trials · doi:10.1016/s0197-2456(99)00022-7 · Cited by 164
Loop Diuretic Infusion Increases Thiazide-Sensitive Na+/Cl--Cotransporter Abundance
Abdallah, J. G., Schrier, R. W., Edelstein, C. L., Jennings, S. D., Wyse, B. D., & Ellison, D. H. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271335 · Cited by 155
Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure
Mentz, R. J., Stevens, S. R., DeVore, A. D., Lala, A., Vader, J. M., AbouEzzeddine, O. F., Khazanie, P., Redfield, M. M., Stevenson, L. W., O’Connor, C. M., et al. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.09.003 · Cited by 128
Self-citation
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationStandards of Care for the Health of Transgender and Gender Diverse People, Version 8
Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L. C., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., et al. (2022) · International Journal of Transgender Health · doi:10.1080/26895269.2022.2100644 · Cited by 2,698
Rangaswami, J., Bhalla, V., Blair, J. E. A., Chang, T. I., Costa, S., Lentine, K. L., Lerma, E. V., Mezue, K., Molitch, M., Mullens, W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000664 · Cited by 1,409
Self-citationMullens, W., Damman, K., Harjola, V.-P., Mebazaa, A., Brunner-La Rocca, H.-P., Martens, P., Testani, J. M., Tang, W. H. W., Orso, F., Rossignol, P., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1369 · Cited by 1,119
Self-citation
Metadata
- Authors
- Butler, J., Anstrom, K. J., Felker, G. M., Givertz, M. M., Kalogeropoulos, A. P., Konstam, M. A., Mann, D. L., Margulies, K. B., McNulty, S. E., Mentz, R. J., Redfield, M. M., Tang, W. H. W., Whellan, D. J., Shah, M., Desvigne-Nickens, P., Hernandez, A. F., Braunwald, E., & for the National Heart Lung and Blood Institute Heart Failure Clinical Research Network
- Venue
- JAMA Cardiology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-09-01
- Volume
- 2
- Issue
- 9
- Pages
- 950
- ISSN
- 2380-6583 (ISSN-L)
- OpenAlex
- W2736262452
- Cited by
- 321
- References
- 19
- FWCI
- 16.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamacardio.2017.2198
- The paper
- Butler, J., Anstrom, K. J., Felker, G. M., Givertz, M. M., Kalogeropoulos, A. P., Konstam, M. A., Mann, D. L., Margulies, K. B., McNulty, S. E., Mentz, R. J., Redfield, M. M., Tang, W. H. W., Whellan, D. J., Shah, M., Desvigne-Nickens, P., Hernandez, A. F., Braunwald, E., & for the National Heart Lung and Blood Institute Heart Failure Clinical Research Network. (2017). Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiology. https://doi.org/10.1001/jamacardio.2017.2198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.